MiguelAEscobarMD

PubMed

• Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.
  Jacqueline N Poston, Cassandra Bryan, Annette von Drygalski, Kadhim Al Banaa, Jenny Y Zhou
  Blood Advances. 2024-11-26
• Simultaneous hemorrhage and venous thrombosis in a patient with systemic lupus erythematosus.
  Binoy Yohannan, Natalie A Montanez, Miguel A Escobar
  Cleveland Clinic Journal of Medicine. 2024-05-01
• Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia.
  Ingrid Pabinger, Mila Ayash-Rashkovsky, Miguel Escobar, Barbara A Konkle, María Eva Mingot-Castellano
  Gene Therapy. 2024-05-01

Journal Articles

• Switching patients in the age of long-acting recombinant products?  
  Escobar, M. Santagostino E, Mancuso ME, Coppens M, et al., Expert Review of Hematology, 1/1/2019
• Identification and characterization of novel mutations implicated in congenital fibrinogen disorders  
  Smith N, Bornokova L, Noetzli L, Guglielmone H, Minoldo S, Backos D, Jacobson L, Thornburn C, Escobar M, et al., Research and Practice in Thrombosis and Haemostasis, 1/1/2018
• cross-sectional analysis of cardiovascular disease in the hemophilia population  
  Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang T, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Whee..., Blood Advances, 1/1/2018
• Unnecessary use of inferior vena cava filters: a teachable moment  
  Goswamy RV, Maiti A, Escobar MA, JAMA Intern Med, 1/1/2017
• Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studie...  
  Young G, Escobar MA, Pipe SW, Cooper DL, Am J Hematol, 1/1/2017
• Major and minor classifications for surgery in people with hemophilia: A literature review  
  Solimeno LP, Escobar MA, Krassova S, Seremetis S, Clin Appl Thromb Hemost., 1/1/2017
• Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX  
  Escobar MA, Tehranchi R, Karim A, Caliskan U, Chowdary P, et al., Haemophilia, 1/1/2017
• Providing hemostatic and blood conservation options for Jehovah�s witness patients in a large medical system  
  Bai, Y., Castillo, BS., Tchakarov, A., Escobar, MA., Cotton, BA., et al., Annals of Clinical & Laboratory Science, 1/1/2016
• Efficacy and safety of rVIII-SingleChain: results of a phase I/III multicenter clinical trial in severe hemophilia A  
  Mahlangu J, Kuliczkowski K, Abdul Karim F, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellman A, Santagostino E, Baker RI, ..., Blood, 1/1/2016
• Antifactor Xa levels vs activated partial thromboplastin time for monitoring unfractionated heparin A pilot study  
  Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, and Choi HA, Journal of Clinical Pharmacy and Therapeutics, 1/1/2016
• Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery  
  Escobar MA, G. Auerswald, S. Austin, J. N. Huang, M. Norton and C. M. Millar, Haemophilia, 1/1/2016
• Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital hemophilia with inhibitors  
  Santagostino E, Escobar M, Ozelo M, Solimeno L, et al., Blood Reviews, 1/1/2015
• Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening  
  Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, Escobar MA, et al., Am J Hematol, 1/1/2015
• Optimising musculoskeletal care for patients with haemophilia  
  Carcao M, Hilliard P, Escobar M, Solimeno L, Mahlangu J, Santagostino E, Eur J Haematol, 1/1/2015
• Advances in the treatment of inherited coagulation disorders  
  Escobar, M.A., Haemophilia, 1/1/2013
• Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis  
  Escobar, M.A., Sallah, S., Journal of Thrombosis and Haemostasis, 1/1/2013
• Bleeding in the Patient with a Malignancy  
  Escobar, M.A., Cancer, 1/1/2012
• Total joint replacement in advanced haemophilic arthropathy: A review of outcome, complications, impact of HIV and Inhibitors  
  Rodriguez-Merchan, EC, Rodriguez, NI, Escobar, M.A., Journal of Clinical Rheumatology & Musculoskeletal Medicine, 1/1/2012
• Utilization Patterns and Associated Costs of Factor Assistance Programs among Persons with Hemophilia: A Single Institution Review  
  Khleif, A., Rodriguez, N., Brown, D., Escobar, M.A., Haemophilia, 1/1/2012
• Best Practices for the Multidisciplinary Management of Patients with Hemophilia with Inhibitors Undergoing Surgery in the United States  
  Escobar, M.A, Maahs, J, Hellman, E, Donkin, J, Forsyth, A, Hroma, N, et al., Haemophilia, 1/1/2012
• Multiple Co-morbid Conditions Among Middle-aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care  
  Khleif, A., Rodriguez, N., Brown, D., and Escobar, M.A., Journal of Aging Research, 1/1/2011
• In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study  
  Kempton CL, Soucie FM, Miller CH, Hooper C, Escobar M.A., Cohen AJ, Key NS, Thompson AR, and Abshire TC, J Thromb Haemost, 1/1/2010
• Back to the future: covalent epitope-based HIV vaccine development  
  Paul, S., Planque, S., Nishiyama, Y., Escobar, M., Hanson, C., Expert Review Vaccines, 1/1/2010
• Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120�CD4-binding site from long-term survivors of HIV infection  
  Planque, S., Salas, M., Mitsuda, Y., Sienczyk, M., Escobar, M.A., et.al., AIDS, 1/1/2010
• Health Economics in Haemophilia: A review from the clinician�s perspective  
  Escobar, M.A., Haemophilia, 1/1/2010
• Join now to see all

Books/Book Chapters

• Management of Bleeding Patients 
  Chapter: Known bleeding disorders for surgery. 
  Escobar, M.A., Nguyen T.T., Montanez N.Editors: J. Teruya.SpringerEdition 2,2021
• Williams Hematology 
  Chapter: Hemophilia A and Hemophilia B 
  Escobar, MA and Reding M.Editors: Beutler E., et al..McGraw HillEdition 10,2021
• Consultative Hemostasis and Thrombosis 
  Chapter: Less common congenital disorders of hemostasis. 
  Escobar, MA.Editors: CS Kitchens, et al..W.B. Saunders CompanyEdition 4,2019
• The Core Topics of Aortic Disease 
  Chapter: Strategy for heparin-induced thrombocytopenia and anticoagulation replacement therapy. 
  Hall AC and Escobar MAEditors: S Zhou and A Estrera.Liaoning Science and Technology Publishing House2018
• Encyclopedia of Human Biology 
  Chapter: Hemophilia 
  Escobar, M.A., Nguyen T.T.Willey-Blackwell2014
• Textbook of Haemophilia 
  Chapter: Products used to treat haemophilia: Dosing. 
  Escobar M.A.Editors: Lee, K Hoots and E Berntop.Blackwell Publishing2014
• Hemophilia and Hemostasis: A Case-Based Approach to Management 
  Ma, DA., Roberts, HR., Escobar, MAWilley-BlackwellEdition Seco,2012
• Williams Hematology 
  Chapter: Hemophilia A and Hemophilia B 
  Roberts, H.R., Key, N., Escobar, M.A.Editors: Beutler E., et al..McGraw HillEdition Eigh,2010
• Textbook of Haemophilia 
  Chapter: Products used to treat haemophilia: Dosing 
  Escobar M.A.Editors: C Lee, K Hoots and E Berntop.Blackwell Publishing2010
• Evidence- based Hematology 
  Chapter: Diagnosis and management of acquired bleeding disorders: Vitamin K antagonists. 
  Escobar, M.A.Editors: Crowther, M., Ginsberg, J., et al..Blackwell Publishing2008
• Lange Q&A. USMLE Step 3 Fifth Edition 
  Brisco, A.D.; Escobar, MA (Contributor)McGraw-HillEdition 5th,2007
• Lange Q&A. USMLE Step 3 Fourth Edition 
  Brisco, A.D.; Escobar, MA (Contributor)McGraw-HillEdition 4th,2007
• PocketMedicine/Internal Medicine 
  Chapter: Thrombophilia. 
  Escobar, M.A., Roberts, H.R. and Ma, A.Editors: B.F. Scharschmidt.2007
• Hemostasis and Thrombosis: basic principles and clinical practice 
  Chapter: Inherited disorders of prothrombin conversion. 
  Roberts, H.R., Escobar, M.A.Editors: Colman RW, Hirsh J, Marder VJ et al..Lippincott Williams & WilkinsEdition Fift,2006
• Textbook of Haemophilia 
  Escobar M.A.Editors: C Lee, K Hoots and E Berntop.Blackwell Publishing2005
• Hematology: Basic Principles and Practice. 
  Chapter: Other clotting factor deficiencies. 
  Roberts, HR, Escobar, M.A.Editors: Hoffman R., et al..Churchill LivingstoneEdition Four,2005
• Thrombosis and Hemorrhage. 
  Chapter: Other coagulation factor deficiencies. 
  Roberts, H.R. and Escobar, M.A.Editors: J Loscalzo and AI Schafer.Williams & Wilkins CompanyEdition Thir,2002
• Pocket Medicine/Internal Medicine 
  Chapter: Thrombophilia. 
  Escobar, M.A., Roberts, H.R. and Ma, A.Editors: B.F. Scharschmidt.2002
• Hemofilia 
  Chapter: Concentrados purificados en el tratamiento de la hemofilia. 
  Page 389 - 396Escobar, M.A.Editors: CM Murillo, et al..Editorial Prado, S.A.2001
• Join now to see all

Abstracts/Posters

• The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, ...
  Miguel A. Escobar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies (Inhibitors) Directed Against Therapeuti...
  Miguel A. Escobar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study.
  Sood SL, Cheng D, Shapiro AD, Kessler CM,Key NS, Quon DV, Eyster E, Manco-Johnson MJ, Kempton CL,Cuker A, Ragni MV, Gill JC, Kuriakose P, Drygalski A, Kouides PA, Esco..., American Society of Hematology Annual meeting, San Diego, CA, 1/1/2018
• Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from 2 Clinical Trials).
  P Chowdary, L Poulsen, M Escobar, S Kearney, et al., American Society of Hematology Annual meeting, San Diego, CA, 1/1/2018
• Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment.
  Escobar M, Walsh C, Cooper D, Young G, National Hemophilia Foundation Meeting, 1/1/2018
• Coagulation Factor Use Evaluation at an Academic Medical Center.
  Grego AR, Okuboyejo J, Escobar M, Academy of Managed Care Pharmacy Meeting (AMCP), 1/1/2018
• Pharmaco-economic analysis of direct thrombin inhibitors using IgG Specific ELISA antibodies in suspected heparin induced thrombocytopenia.
  Samuel S, McGuire MF, Cortes J, Weeks P, Brown RS, Nguyen A, Escobar M, THSNA, 1/1/2018
• Pharmacoeconomic analysis of direct thrombin inhibitors using polyspecific ELISA antibodies in suspected heparin induced thrombocytopenia.
  Samuel S , McGuire MF, Cortes J, Weeks P, Brown RS, Nguyen A, Escobar M, Thrombosis & Hemostasis Societies of North America (THSNA), 1/1/2018
• Comparison of rFIX utilization and bleed rates in US hemophilia B patients on rIX-FP and their prior rFIX drug.
  Escobar M, Leissinger C, Yan S, Maro G, Krishnarajah G, Res Prac Thromb Haemost, 1/1/2018
• Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study.
  Sood SL, Cheng D, Shapiro AD, Kessler CM,Key NS, Quon DV, Eyster E, Manco-Johnson MJ, Kempton CL,Cuker A, Ragni MV, Gill JC, Kuriakose P, Drygalski A, Kouides PA, Esco..., THSNA, 1/1/2018
• Safety and efficacy of N9-GP, a recombinant glycoPEGylated factor IX with extended half-life, in US vs global patients with hemophilia B: results from the paradigm� cl...
  Young G, Lentz SR, Kearney S, Escobar M, Seremetis S, Cooper DL, Walsh C, THSNA, 1/1/2018
• Low dose 4-factor Prothrombin Complex Concentrate in reversal of Xa Inhibitors in a Neuro ICU.
  AllisonT, Hartman H, Gass J, Lin PJ, Chong K, Choi HA and Escobar M', Society of Critical Care Medicine annual Congress� Texas Chapter. Winner of the Alan I. Fields Award; Critical Care Congress, Honolulu, HI, 2016, 1/1/2017
• Prophylaxis with rIX-FP reduces consumption compared with previous FIX in both adult and pediatric patients.
  M Escobar, E Santagostino, C Leissinger, A Shapiro, J Oldenburg, B Pan-Petesch, Wilfried Seifert, the PROLONG-9FP Investigators, XXVI Congress of the International Society of Thrombosis and Haemostasis; Res Prac Thromb Haemost, Berlin, Germany, 1/1/2017
• Prediction of outcome in acquired hemophilia A.
  Escobar M, Donnachie E, XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Characterization of the HLA-class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome by FVIII Domain and HLAcII Isomer.
  Almeida M, Diego VP, Luu BW, Hofmann M, Garcia-Hern�ndez A, Peralta J, Curran J, Escobar M, et al., XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Consumption of rVIII-SingleChain during prophylaxis in adult, adolescent and pediatric patients.
  Pabinger i, Fischer K, Gill J, Santagostino E, Boggio L, Escobar M and Mahlangu J, XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant factor VI...
  Young G, Quon DV, Escobar MA, Boggio LN, et al., XXV-I Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• La profilaxis con rIX-FP reduce el consumo en comparaci�n con el concentrado de FIX anterior en pacientes adultos y pedi�tricos.
  Spanish Hemophilia Society Meeting, 1/1/2017
• Characterization of the HLA-class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome by FVIII Domain and HLAcII Isomer.
  Almeida M, Diego VP, Luu BW, Hofmann M, Garcia-Hern�ndez A, Peralta J, Curran J, Escobar M, et al., American Society of Hematology Annual meeting, Atlanta, GA, 1/1/2017
• Once-weekly prophylaxis with GlycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from a randomized phase 3 trial (pathf...
  Curry N, Albayrak C, Escobar M, Holme PA, Kearnev S, et al., XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia.
  Escobar MA, Smith KC, Donnachie E, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thromb...
  Gustafson S, Lee M, Gonzaga C, and Escobar MA, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US.
  Lemons J, Brown D, Cantini M, Cannon K, Rodriguez N, Nguyen T, and Escobar M, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Prophylactic Efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis.
  Escobar M, Young G, Oldenburg J, Mahlangu J, et al., Thrombosis and Hemostasis Summit of North America (THSNA) Meeting, Chicago, IL, 1/1/2016
• Update on a phase � open-label trial of BAX 335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B.
  Monahan P, Walsh C, Konkle B, Powell J, Josephson N, Escobar M., et al., National Hemophilia Foundation 67th Annual Meeting, Dallas, TX, 1/1/2015
• Join now to see all

Lectures

• Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Res... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Therapeutic Options in Hemophilia 
  Mexico City, MX - 1/1/2018
• New Treatments in Hemophilia, including gene therapy 
  Nuevo Vallarta, Mexico - 1/1/2018
• How can we Decrease the Risk of inhibitors in Hemophilia 
  Nuevo Vallarta, Mexico - 1/1/2018
• �New Treatment Strategies for the Treatment of Bleeding Disorders� 
  University of Texas Health Science Center at Houston - 1/1/2017
• �New Treatment Strategies for Hemophilia Management� 
  Republica Dominicana - 1/1/2017
• �Standard of Care for Hemophilia in the Developed World�. 
  Republica Dominicana - 1/1/2017
• �Prophylaxis in hemophilia. New therapeutic options.� 
  Chicago, IL - 1/1/2015
• �Treatment Options for prophylaxis in hemophilia�. 
  Texas Children's Hospital, Houston, TX - 1/1/2015
• �DIC, Bleeding Disorders and Coagulopathy�. 
  Houston, TX - 1/1/2015
• �One in a Million: Rare Bleeding Disorders� 
  Dallas, TX - 1/1/2015
• �Rare Bleeding Disorders� 
  Dallas, TX - 1/1/2015
• �Management of Comorbidities in Hemophilia and vonWillebrand Disease� 
  Sao Paulo, Brazil - 1/1/2015
• �New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins�. 
  Bethesda, MD - 1/1/2015
• �Management of other comorbidities in hemophilia� 
  Caracas, Venezuela - 1/1/2015
• �Appropriate Use of Blood Components in a Modern Acute Care Hospital� 
  Houston, TX - 1/1/2014
• �Blood Utilization Program� 
  Memorial Hermann Hospital, TMC - 1/1/2014
• �Hemophilia Care in Developed Countries�. 
  Panama City, Panama - 1/1/2014
• �Ask the Experts: inhibitors in Hemophilia� 
  Washington, DC - 1/1/2014
• �Update on Coagulation Assays. More Than Just PT/PTT� 
  Cali, Colombia - 1/1/2014
• �Emerging Coagulation Factors for Hemophilia� 
  Cali, Colombia - 1/1/2014
• �New Oral Anticoagulants� 
  University of Texas Health Science Center at Houston - 1/1/2013
• �Prophylaxis in Hemophilia�. 
  Mexico City - 1/1/2013
• �Management of Patients with inhibitors� 
  1/1/2013
• Join now to see all